HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors
brief summary
A Phase I Study of HEC-921 Injection as Monotherapy and in Combination with Other AntineoplasticTherapy in Patients with Advanced Malignant Solid Tumors
detailed description
This is a Phase I open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD) characteristics, immunogenicity and antitumor activity of HEC-921 injection as monotherapy and in combination with other antineoplastic therapies in patients with advanced malignant tumors. The recommended Phase II dose (RP2D) will be determined based on safety, tolerability, and pharmacokinetics.
official title
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HEC-921 Injection as Monotherapy and in Combination With Other Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors